FDA approves OTC naloxone nasal spray Rextovy, expanding consumer access to overdose treatment
The FDA announced approval of a new over-the-counter naloxone nasal spray called Rextovy, delivering 4 mg of naloxone hydrochloride for emergency reversal of opioid overdose.
The product can be purchased without a prescription at pharmacies, convenience stores and online, supporting federal initiatives to broaden access to life-saving medication.
Officials said that adding another OTC naloxone option enables people without medical training to act quickly, which has been shown to lower overdose deaths.
The approval expands the range of available naloxone nasal sprays, increasing market choices for consumers seeking rapid overdose response.
This writeup was produced by pharmadog from original reporting by fda press.
Original headline: “FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose”
read at fda press ↗
comments(0)
5-min edit window · permanent after that